Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
bms.com

See what CB Insights has to offer

Investments

51

Portfolio Exits

14

Partners & Customers

10

Service Providers

1

About Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases.

Bristol-Myers Squibb Headquarter Location

430 E. 29th Street 14th Floor

New York, New York, 10016,

United States

800-332-2056

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bristol-Myers Squibb

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bristol-Myers Squibb in 2 Expert Collections, including Digital Health.

D

Digital Health

419 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Bristol-Myers Squibb Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bristol-Myers Squibb Rank

Research containing Bristol-Myers Squibb

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Bristol-Myers Squibb in 3 CB Insights research briefs, most recently on Apr 19, 2021.

Latest Bristol-Myers Squibb News

CVS Caremark returns Eliquis to formulary after outcry

Jun 22, 2022

CVS Health will return blood thinner Eliquis to its pharmacy benefit manager's commercial formulary beginning July 1, reversing a decision that sparked protests from physicians and patients, the company notified providers last week. CVS Caremark negotiated a new arrangement with Eliquis maker Bristol-Myers Squibb to acquire the prescription anticoagulant. Both Eliquis and Janssen Pharmaceutical's Xarelto will be available to patients the PBM covers. For months, CVS Caremark's formulary included only Xarelto, even though research hasn't shown the two medications to be interchangeable. Patients, medical societies and advocacy groups such as the American College of Cardiology and American Society of Hematology objected when CVS Caremark disclosed last year that Eliquis would leave its formularly. A coalition called the Partnership to Advance Cardiovascular Health described the formulary exclusion as "dangerously disruptive" in a December letter to Dr. Troyen Brennan, then the company's chief medical officer. CVS Caremark decided to return Eliquis to its formulary after negotiating a lower net cost, a spokesperson wrote in an email Tuesday. "Anticoagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases," the spokesperson wrote. The price of Eliquis, also known as apixaban, rose 6% to $529 for a one-month supply in January compared to a year before, according to Patients for Affordable Drugs, an advocacy organization. The cost of Xarelto, also known as rivaroxaban, increased 4.9% during the same period to $516 monthly, the report says. Because pharmacy benefit managers receive rebates from manufacturers for formulary placement, it is unknown how much CVS Caremark pays for these drugs. In addition to returning to CVS Caremark's commercial formulary, Eliquis will receive preferred treatment by CVS Health's Zinc group purchasing organization beginning July 1, a Bristol-Myers Squibb spokesperson wrote in an email. Group purchasing organizations serve as a rebate aggregators for other PBMs. In the months after CVS Caremark announced it would remove Eliquis from its formulary, Bristol-Myers Squibb launched a copay card that allowed some commercially insured patients, including those covered through CVS Caremark, to purchase the medicine for $10 a month. But because these drugs are so widely prescribed, not every physician was aware of this option, so access remained limited, said Dr. Geoffrey Barnes, a cardiologist and a professor at the University of Michigan. Barnes, a consultant to both Bristol-Myers Squibb and Johnson & Johnson-owned Janssen Pharmaceutcal, has discussed the impact of CVS Caremark's formulary exclusion with CVS Health executives, he said. "There is a larger conversation about the cost of medications in general, and how we keep those under control so that they're accessible to all patients," Barnes said. "That's something that's not just controlled by insurers or PBMs, but also by manufacturers. This is a complex problem." Pharmacy benefit managers typically do not reverse formulary decisions or modify coverage options mid-year, said Antonio Ciaccia, CEO of drug pricing research firm 46brooklyn Research and president of 3 Axis Advisors consultancy. "It shows you that an activated, pissed off and loud group of patients can impact PBM decisions that work against their wellbeing," he said. Patient and advocate Beth Joyner Waldron of Chapel Hill, North Carolina, has been a vocal critic of CVS Caremark's formulary change. Although her employer restored Eliquis to its drug list in February, Joyner Waldron, 52, sustained public pressure on CVS Health and its executives on social media, and credits patient activism with the company's shift. "This was an example of collective action," she said. The formulary change will take effect one month after the Federal Trade Commission announced an investigation of pharmacy benefit manager business practices Regulators will require CVS Caremark and the five other largest PBMs to reveal information about their operations to guage how their activities influence drug pricing and access. CVS Caremark, Cigna's Express Scripts and UnitedHealth Group's OptumRx collectively control about 80% of the PBM market, according to the FTC. Letter

Bristol-Myers Squibb Investments

51 Investments

Bristol-Myers Squibb has made 51 investments. Their latest investment was in Owkin as part of their Corporate Minority on June 6, 2022.

CBI Logo

Bristol-Myers Squibb Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/8/2022

Corporate Minority

Owkin

$80M

Yes

4

5/31/2022

Series B

Sapience Therapeutics

$41M

No

1

5/11/2022

Series A

Nuvig Therapeutics

$47M

Yes

3

4/21/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/14/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/8/2022

5/31/2022

5/11/2022

4/21/2022

4/14/2022

Round

Corporate Minority

Series B

Series A

Series B

Series B

Company

Owkin

Sapience Therapeutics

Nuvig Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$80M

$41M

$47M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

1

3

10

10

Bristol-Myers Squibb Portfolio Exits

14 Portfolio Exits

Bristol-Myers Squibb has 14 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/23/2021

Acquired

$99M

12

10/1/2021

IPO

$99M

3

3/26/2021

IPO

$99M

7

2/3/2021

Divestiture

Subscribe to see more

Subscribe to see more

10

12/4/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/23/2021

10/1/2021

3/26/2021

2/3/2021

12/4/2020

Exit

Acquired

IPO

IPO

Divestiture

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

12

3

7

10

10

Bristol-Myers Squibb Acquisitions

18 Acquisitions

Bristol-Myers Squibb acquired 18 companies. Their latest acquisition was Turning Point Therapeutics on June 03, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/3/2022

Series D

$99M

$144.43M

Acq - Pending

4

11/17/2020

Series B

$99M

$94M

Acq - P2P

8

8/24/2020

Series C

$99M

$18.8M

Acquired

10

11/21/2019

Subscribe to see more

$99M

Subscribe to see more

10

8/3/2017

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

6/3/2022

11/17/2020

8/24/2020

11/21/2019

8/3/2017

Investment Stage

Series D

Series B

Series C

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$144.43M

$94M

$18.8M

$99M

Note

Acq - Pending

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

4

8

10

10

10

Bristol-Myers Squibb Partners & Customers

10 Partners and customers

Bristol-Myers Squibb has 10 strategic partners and customers. Bristol-Myers Squibb recently partnered with Immatics Biotechnologies on June 6, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

6/2/2022

Partner

Germany

1

6/2/2022

Licensor

Germany

7

5/12/2022

Licensor

United States

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

In July 2021 , BridgeBio Pharma , Inc. initially announced a non-exclusive , co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® in patients with advanced solid tumors with KRAS mutations .

1

5/4/2022

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

5/4/2022

Licensor

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

6/2/2022

6/2/2022

5/12/2022

5/4/2022

5/4/2022

Type

Partner

Licensor

Licensor

Partner

Licensor

Business Partner

Country

Germany

Germany

United States

United Kingdom

United Kingdom

News Snippet

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

In July 2021 , BridgeBio Pharma , Inc. initially announced a non-exclusive , co-funded clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® in patients with advanced solid tumors with KRAS mutations .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

7

1

10

10

Bristol-Myers Squibb Service Providers

1 Service Provider

Bristol-Myers Squibb has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Bristol-Myers Squibb Team

157 Team Members

Bristol-Myers Squibb has 157 team members, including current Founder, President, Suresh Poosala.

Name

Work History

Title

Status

Suresh Poosala

National Institutes of Health, and St. Jude Children's Research Hospital

Founder, President

Current

Lamberto Andreotti

Chief Executive Officer

Current

Giovanni Caforio

Chief Executive Officer

Current

Nadim Ahmed

President, Executive Vice President

Current

Teresa M Foy

President, Senior Vice President

Current

Name

Suresh Poosala

Lamberto Andreotti

Giovanni Caforio

Nadim Ahmed

Teresa M Foy

Work History

National Institutes of Health, and St. Jude Children's Research Hospital

Title

Founder, President

Chief Executive Officer

Chief Executive Officer

President, Executive Vice President

President, Senior Vice President

Status

Current

Current

Current

Current

Current

You May Also Like

D
DoubleRainbow Biosciences

DoubleRainbow Biosciences develops technologies rooted in the mechanistic understanding of specialized metabolic systems in plants and other organisms. The firm devises biosynthetic strategies that provide sustainable access to high-value natural products of medicinal or industrial significance.

L
Luminary Therapeutics

Luminary Therapeutics is a biotechnology company based in Minneapolis, Minnesota.

G
GI Innovation

GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

Novartis Logo
Novartis

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Kite Pharma Logo
Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.

Johnson & Johnson Logo
Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a multi-national manufacturer of pharmaceutical, diagnostic, therapeutic, surgical, and biotechnology products, as well as personal hygiene products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.